Publications by authors named "Yusuke Oji"

Claim this Profile
P
Predictors of patients with advanced pancreatic cancer undergoing conversion surgery via chemoimmunotherapy with a multifunctional Wilms' tumor 1 (WT1) peptide cocktail-pulsed dendritic cell vaccine.
Shigeo Koido, Junichi Taguchi, Masamori Shimabuku, Tuuse Bito, Soyoko Morimoto, Yusuke Oji

J Immunother Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant.
Shunya Ikeda, Kana Hasegawa, Yosuke Kogue, Takao Arimori, Ryuhei Kawamoto, Yusuke Oji

Nat Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome.
Zwi N Berneman, Maxime De Laere, Paul Germonpré, Manon T Huizing, Yannick Willemen, Yusuke Oji

J Hematol Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome.
Zwi N Berneman, Maxime De Laere, Paul Germonpré, Manon T Huizing, Yannick Willemen, Yusuke Oji

J Hematol Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spontaneous high clonal expansion of Wilms' tumor gene 1-specific cytotoxic T-lymphocytes in patients with Wilms' tumor gene 1-expressing solid tumor.
Soyoko Morimoto, Yukie Tanaka, Jun Nakata, Fumihiro Fujiki, Kana Hasegawa, Yusuke Oji

Cancer Immunol Immunother· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzyme-Linked Immunosorbent Assay for Antibodies Against the Tumor-Associated Antigen-Derived Cytotoxic T-Lymphocyte Epitope.
Yusuke Oji

Methods Mol Biol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs.
Fumihiro Fujiki, Soyoko Morimoto, Yuya Nishida, Satoe Tanii, Nao Aoyama, Yusuke Oji

Cancer Immunol Immunother· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1.
Yusuke Oji, Naoki Kagawa, Hideyuki Arita, Norifumi Naka, Ken-Ichiro Hamada

Cancers (Basel)· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T Cell-Intrinsic Vitamin A Metabolism and Its Signaling Are Targets for Memory T Cell-Based Cancer Immunotherapy.
Fumihiro Fujiki, Soyoko Morimoto, Akiko Katsuhara, Akane Okuda, Saeka Ogawa, Yusuke Oji

Front Immunol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum WT1-271 IgM antibody as a novel diagnostic marker for Gastric Cancer.
Masaaki Ito, Yusuke Oji, Mayuko Adachi, Rin Imanishi, Shouq Alzaaqi

Mol Clin Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine.
Shouq Alzaaqi, Norifumi Naka, Kenichiro Hamada, Naoki Hosen, Mizuki Kanegae, Yusuke Oji

Oncol Lett· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain.
Kana Hasegawa, Shunya Ikeda, Moto Yaga, Kouki Watanabe, Rika Urakawa, Yusuke Oji

Sci Transl Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy.
Chisato Yokota, Naoki Kagawa, Koji Takano, Yasuyoshi Chiba, Manabu Kinoshita, Yusuke Oji

Cancer Immunol Immunother· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cellular and Humoral Immune Responses Induced by an HLA Class I-restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer.
Sumiyuki Nishida, Soyoko Morimoto, Yusuke Oji, Satoshi Morita, Toshiaki Shirakata

J Immunother· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of mouse helper epitopes for WT1-specific CD4 T cells.
Hiroko Nakajima, Jun Nakata, Kanako Imafuku, Hiromu Hayashibara, Kazuki Isokawa, Yusuke Oji

Cancer Immunol Immunother· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imaging Assessment of Tumor Response in the Era of Immunotherapy.
Jun Nakata, Kayako Isohashi, Yoshihiro Oka, Hiroko Nakajima, Soyoko Morimoto, Yusuke Oji

Diagnostics (Basel)· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct difference in tumor-infiltrating immune cells between Wilms' tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies.
Chisato Yokota, Jun Nakata, Koji Takano, Hiroko Nakajima, Hiromu Hayashibara, Yusuke Oji

Neurooncol Adv· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides.
Fumihiro Fujiki, Akihiro Tsuboi, Soyoko Morimoto, Naoya Hashimoto, Miki Inatome, Yusuke Oji

Cancer Immunol Immunother· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced immune reaction resulting from co-vaccination of WT1 helper peptide assessed on PET-CT.
Jun Nakata, Kayako Isohashi, Soyoko Morimoto, Ryota Itou, Takashi Kamiya, Yusuke Oji

Medicine (Baltimore)· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Encouraging Clinical Evolution of a Pediatric Patient With Relapsed Diffuse Midline Glioma Who Underwent WT1-Targeting Immunotherapy: A Case Report and Literature Review.
Yoshiko Hashii, Yoshihiro Oka, Naoki Kagawa, Naoya Hashimoto, Hiroyuki Saitou, Yusuke Oji

Front Oncol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reader-free ELISPOT assay for immuno-monitoring in peptide-based cancer vaccine immunotherapy.
Sae Hayashi, Rin Imanishi, Mayuko Adachi, Sayaka Ikejima, Jun Nakata, Yusuke Oji

Biomed Rep· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune adjuvant therapy using Bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments.
Sumiyuki Nishida, Akihiro Tsuboi, Atsushi Tanemura, Toshinori Ito, Hiroko Nakajima, Yusuke Oji

Medicine (Baltimore)· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What should we tackle next in acute myeloid leukemia? Wilms tumor gene 1 vaccine therapy would be a promising and versatile strategy for acute myeloid leukemia.
Jun Nakata, Yusuke Oji, Yoshihiro Oka, Haruo Sugiyama

Expert Rev Hematol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.
Akihiro Tsuboi, Naoya Hashimoto, Fumihiro Fujiki, Soyoko Morimoto, Naoki Kagawa, Yusuke Oji

Cancer Immunol Immunother· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides.
Jun Nakata, Hiroko Nakajima, Hiromu Hayashibara, Kanako Imafuku, Soyoko Morimoto, Yusuke Oji

Oncotarget· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis